Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT162b3 Safety and Immunogenicity in Healthy Adults
NCT04537949Phase 2Completed
- Sponsor
- BioNTech SE
- Start
- Sep 2020
- Primary completion
- Mar 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BNT162b3 in coronavirus disease 2019 (COVID-19), sponsored by BioNTech SE. Started Sep 2020; status: completed.
02
Drugs
BNT162b3
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04537949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04537949.